Stay updated with breaking news from Nasdaq Stsa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi purchased 22,053,581 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was bought at an average price of $0.91 per share, for a total transaction of $20,068,758.71. Following the purchase, the director now directly owns 24,847,694 shares in […]
Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) and Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation. Earnings & Valuation This table compares Satsuma Pharmaceuticals and […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 130,100 shares, a decrease of 58.0% from the April 30th total of 310,100 shares. Approximately 0.5% of the shares of the stock are sold […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 130,100 shares, a decline of 58.0% from the April 30th total of 310,100 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is […]
Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) and Catalent (NYSE:CTLT – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership. Earnings and Valuation This table compares Satsuma Pharmaceuticals and Catalent’s revenue, […]